Posted on Tuesday, 2 March 2010 by
John Carroll
CombinatoRx's complex merger deal with Neuromed will pay off with a $40 million milestone earned with today's announcement that the FDA has approved Exalgo, a once-daily pain therapy. Covidien, which partnered on the program, will handle the commercial rollout and fork over the cash.
Read the full article at FierceBiotech